THIRD-PARTY REVIEW PILOT'S POTENTIAL LONG-TERM BENEFITS JUSTIFY COMPANY PARTICIPATION, FDA'S PHILLIPS SAYS; DEVICE INDUSTRY REPS CRITICIZE PILOT PROGRAM
This article was originally published in The Gray Sheet
Executive Summary
Manufacturers should look to the potential long-term benefits of a third-party device review pilot in deciding whether to participate in the program, Philip Phillips, deputy director of the Office of Device Evaluation in FDA's Center for Devices and Radiological Health, said Sept. 9 at the Regulatory Affairs Professionals Society annual meeting in Washington, D.C.